Mark Therapeutics, Inc.

San Diego, CA

UEI
CJ5HCCFMA3K5
CAGE
9FAM3
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
  • Woman Owned Small Business
  • Woman Owned Business
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
9276 Scranton Rd #500, San Diego, CA 92121, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Mark Therapeutics, Inc.'s 2 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Gene therapy for idiopathic parkinson's disease: in vivo validation - idiopathic parkinson's disease (idpd) affects over… Grant · R44NS134446 National Institute of Neurological Disorders and Stroke $862,457
Gene therapy for idiopathic parkinson's disease - there is no cure or disease-modifying therapy for patients diagnosed… Grant · R43NS134446 National Institute of Neurological Disorders and Stroke $686,284

Quick answers

What is Mark Therapeutics, Inc.'s UEI?

Mark Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is CJ5HCCFMA3K5.

What is Mark Therapeutics, Inc.'s CAGE code?

Mark Therapeutics, Inc.'s CAGE code is 9FAM3.

What is Mark Therapeutics, Inc.'s primary NAICS code?

Mark Therapeutics, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Mark Therapeutics, Inc. located?

Mark Therapeutics, Inc.'s physical address in SAM.gov is 9276 Scranton Rd #500, San Diego, CA 92121, USA.

Is Mark Therapeutics, Inc. registered in SAM.gov?

Yes. Mark Therapeutics, Inc.'s SAM.gov registration is active through February 17, 2027.

What is Mark Therapeutics, Inc.'s most recent federal award?

Mark Therapeutics, Inc.'s most recent federal grant award is Gene therapy for idiopathic parkinson's disease: in vivo validation - idiopathic parkinson's disease (idpd) affects over… (R44NS134446), from National Institute of Neurological Disorders and Stroke, on September 1, 2024.

On GovTribe

See Mark Therapeutics, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login